Investors may be waiting until 2021 before a Covid-19 vaccine becomes available, according to quantitative pioneers PanAgora Asset Management Inc.

The Boston-based systematic asset manager is using its ability to parse vast quantities of medical research data to infer whether any of approximately 60 trials currently under way will succeed in producing a successful vaccine, said George Mussalli, chief investment officer and head of equity research at PanAgora. Their findings may disappoint those hoping that access to one soon will boost markets.”

View Here